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Silver–coumarin–phenanthroline complexcurrent study was to investigate the potential in vitro anti-proliferative effect of
4-hydroxy-3-nitro-coumarin (hncH), and the mixed-ligand silver (I) complex of 4-oxy-3-nitro-coumarin-bis
(phenanthroline), [Ag(hnc)(phen)2] using four human-derived model cell lines. In addition, selected
mechanistic studies were carried out using the most sensitive of the four cell lines. Results obtained show
that the complex could decrease the proliferation of all four cell lines including neoplastic renal and hepatic,
namely A-498 and HepG2 cells, respectively, along with two non-neoplastic renal and hepatic cell lines, HK-2
and Chang, respectively. Furthermore, non-neoplastic hepatic cells (Chang) appeared to be less sensitive to
the effect of the complex, but this effect was not replicated in the non-neoplastic renal (HK-2) cells. Based on
IC50 values [Ag(hnc)(phen)2] was shown to be almost four times more potent than cisplatin, using HepG2
cells. In addition, the observed anti-proliferative effect was shown to be both dose- and time-dependent.
Furthermore, the complex was shown to decrease DNA synthesis, but did not intercalate with it. Moreover,
there was no evidence that P-glycoprotein-mediated multi-drug resistance was likely to decrease anti-
proliferative activity. Cytological stains, analysis of genomic DNA, and biochemical assays [caspase-3 and -9
and cleaved poly(ADP-ribose)-polymerase protein] showed that cell death appeared to result from apoptosis,
with the possibility of secondary necrosis. Additionally, flow cytometric analysis showed that the complex
functioned through an alteration in cell cycle progression. Taken together, [Ag(hnc)(phen)2] has been shown
to be a more potent anti-proliferative agent than cisplatin, capable of altering key biochemical events leading
to cell death. Additional mechanistic studies are underway to probe more fully its mechanism of action.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThere have been numerous reports where metal-based drugs have
successfully been used in the detection and treatment of a variety of
diseases. These include cisplatin in cancer chemotherapy, ferrochlor-
oquine in malaria, vanadium(IV) in the control of insulin, and
gadolinium-coordinated contrast agents for magnetic resonance ima-
ging (Fricker, 1994; Harpstrite et al., 2007). Platinum-based compounds
have proven to be effective in the systemic treatment of cancer.
Furthermore, only a few other transition metals, including ruthenium
and gallium, have been extensively investigated for their potentialtitute of Technology, Tallaght,
42700.
.
l rights reserved.anti-cancer activity (Galanski et al., 2003; Brabec and Novakova,
2006; Heffeter et al., 2006). Probably the best known metal-based
anti-cancer drug is cisplatin [cis-diamminedichloroplatinum(II)]. It
has been usedwidely in the treatment of cancers, especially testicular
cancer, with a 70–90% cure rate. Cisplatin has been shown to bind to
DNA following displacement of its chloride ions by hydroxyl groups.
Covalent cross-linking leads to the formation of major adducts, which
results in an inhibition of DNA replication and transcription (Zhang
and Lippard, 2003). Furthermore, when combined with other drugs,
cisplatin has successfully been used to treat brain, ovarian, bladder,
and breast cancer (Marzano et al., 2002). The clinical success of
cisplatin is limited by its significant side effects, such as nausea,
vomiting, severe nephrotoxicity, and genotoxicity, along with
resistance (Marzano et al., 2002; Sastry and Kellie, 2005). These
limitations have stimulated a search for other transition metal
complexes which are as or more effective, but with lesser side effects.
204 B. Thati et al. / European Journal of Pharmacology 602 (2009) 203–214Ruthenium complexes have attracted significant attention as
building blocks for novel anti-cancer agents. These have been
regarded as promising alternatives to platinum complexes (Hartinger
et al., 2006; Tan et al., 2008). To date these complexes have been
shown to offer potential over platinum-based compounds due to
reduced toxicity and a novel mechanism of action, along with an
absence of cross resistance (reviewed by Brabec and Novakova, 2006).
Two structurally similar ruthenium(III) coordination compounds
called KP1019 and NAMI-A have completed phase I clinical trial as
anti-tumour agents and have been shown to be active against
platinum-resistant malignancies including colorectal and pulmonary
metastasis of solid tumours (Bouma et al., 2002; Bacac et al., 2004;
Hartinger et al., 2006). The cellular target(s) of anti-tumour ruthenium
complexes have not yet been fully identified. However, it has been
speculated that their activity may be related to their ability to bind to
DNA. In 2008, Lui et al. studied the in vitro anti-tumour activity of
ruthenium(II) polypyridyl complexes. They showed significant activity
with IC50 values in the micromolar range. In addition, they postulated
that DNA binding was central to understanding their mechanism of
action.
Recently, Heffeter et al. (2006) investigated the in vitro anti-
tumour properties of a new lanthanum complex [tris(1,10-phenan-
throline)lanthanum(III) trithiocyanate (KP772)] using a panel of
tumour cells. Results showed IC50 values in the low micromolar
range. These researchers showed that KP772 could induce morpho-
logical and biochemical changes, all of which are consistent with the
induction of apoptotic cell death. In addition, this agent was shown
not to target DNA, although minor induction of cross-linking was
observed. Li et al. (2006) synthesised two lanthanum(III) complexes
containing 2-methylene-1,10-phenanthroline units bridged by alipha-
tic diamines, and determined their in vitro anti-tumour activity.
Results obtained showed that the complexes were more active than
either the ligand or the salt, with DNA intercalation pivotal to
mediating their activity.
Although epidemiological studies have shown that chromium is an
inorganic carcinogen, chromium(III) salts have been shown to be non-
carcinogenic due to their ability to cross the plasma membrane
(Balamurugan et al., 2004). These researchers showed that chromium
(III) complexes containing 1,10-phenanthroline (phen) showed sig-
nificant in vitro anti-tumour activity in the micromolar range. In
addition, they showed that cell death occurred as a result of apoptosis,
possibly as a result of the generation of reactive oxygen species.
Furthermore, its anti-tumour activity appeared to be dependant on
the induction of apoptotic cell death.
Coumarins comprise a very large class of compounds found
throughout the plant kingdom (Murray et al., 1982; Egan et al., 1990).
The bio-activity of coumarin and more complex related derivatives
appears to be based on the coumarin nucleus (Kolodziej et al., 1997;
Jimenez-Orozco et al., 1999; Finn et al., 2001, 2004a). Biological effects
observed include anti-bacterial (Laurin et al.,1999), anti-thrombotic and
vasodilatory (Hoult and Paya, 1996), anti-mutagenic (Pillai et al., 1999),
lipoxygenase and cyclooxygenase inhibition (Kimura et al., 1985;
Hoffmanova et al., 1998), and scavenging of reactive oxygen species, as
well as anti-tumourigenic effects (Maucher et al., 1993; Sharma et al.,
1994; Egan et al.,1997;Hayes et al.,1998; Finn et al., 2004a,b; Thati et al.,
2007a,b). Since the late 1980's, a number of in vivo studies have
investigated the possible use of coumarins in the treatment of renal cell
carcinoma (Marshall et al., 1986, 1994). All of these studies have
demonstrated a significant response rate following coumarin treatment
alone or in combination therapy. The in vitro effects of coumarins on the
growth of renal cell carcinoma-derived cell lines showed that coumarin
and 7-hydroxycoumarin are potent cytotoxic and cytostatic agents
(Marshall et al., 1994). Recent studies carried out in our laboratory
compared the anti-proliferative capability of a series of natural and
synthetic nitro and hydroxylated derivatives of coumarin, including 6-
nitro-7-hydroxycoumarin and 7,8-dihydroxycoumarin, using both renaladenocarcinoma andmalignantmelanoma cell lines. These compounds
were shown to be potent cytotoxic agents, capable of killing cancer cells
by modulation of key biochemical pathways such as mitogen-activated
protein kinases (Finn et al., 2004a,b, 2005a,b).
1,10-Phenanthroline (phen) and its substituted derivatives, both in
the metal-free state and as ligands co-ordinated to transition metals,
have been shown to disturb the functioning of a wide variety of
biological systems (Butler et al., 1969). Furthermore, when metal-free
N,N'-chelating bases are found to be bioactive it is usually assumed
that the sequestering of trace metals in situ is involved, and that the
resulting metal complexes are the active species (MacLeod, 1952;
Dwyer et al., 1969). Previous work has shown that the metal-
phenanthroline complexes, namely [Cu(phen)2(mal)]·2H2O, [Mn
(phen)2(mal)]·2H2O, and [Ag2(phen)3(mal)]·2H2O (malH2=malonic
acid), could inhibit growth of the fungal pathogen Candida albicans
by around 95% at a concentration range of 1.25–5.0 μg/ml (McCann
et al., 2000; Coyle et al., 2003).
A number of reports have shown that metal-based derivatives of
phen were capable of killing cancer cells in vitro. Specifically, Deegan
et al. (2007) showed that Cu(phen)2(mal)]·2H2O was a potent in vitro
anti-proliferative agent, while Heffeter et al. (2006) showed that a
lanthanium complex of phen, namely [tris(1,10-phenanthroline)
lanthanium(III)trithiocyanate] could induce apoptosis in human-
derived cell lines. In both cases the concentrations used were in the
low micromolar range, and over short incubation times. Other
researchers have shown that [Cu(phen)2]2+ is a biologically active
metal–phenanthroline complex (Samuni et al., 1981; Wijker and
Lafleur, 1999). This agent has been shown to promote hydroxyl radical
formation from molecular oxygen by redox-cycling and could there-
fore be considered suitable for stimulating the production of reactive
oxygen species. Transition metal cations such as Cu(II) and Fe(II) bind
to negatively-charged DNA and have been shown to play an important
role in the local formation of OH radicals (Samuni et al., 1981; Wijker
and Lafleur 1999). One of the consequences of high copper levels in
the body has been shown to be an increase in the rate of radical
formation leading to oxidative damage, resulting in disruption of lipid
bilayers due to oxidation and cleavage of vulnerable unsaturated fatty
acid residues of phospholipids (Linder, 2001). Alterations in protein
function have also been shown to be promoted through oxidation of
thiol and possibly amino groups. In addition, researchers have
suggested that gene expression may be altered due to oxidation of
guanosine and adenosine residues in nucleic acids, along with an
alteration in transcription factor/growth factor activities (Linder,
2001). Tsang et al. (1996) reported that incubation of a human hepatic
cell line (Hep-G2) with [Cu(phen)2]2+ resulted in internucleosomal
DNA fragmentation. Zhou et al. (2002) also reported G1-specific
apoptosis in a liver carcinoma cell line (Bel-7402), caused by [Cu
(phen)2]2+. Additionally, this complex was shown to up-regulate the
DNA-binding activity of p53, a molecule know to be pivotal in the
regulation of cell progression, cell survival, and apoptosis (Verhaegh
et al., 1997).
Interest inmetal–coumarin complexes has arisen from the search for
novel lead compounds, along with the desire to improve the
pharmacological profile of established anti-neoplastic agents. Kokotos
et al. (1997) synthesised a number of amino-coumarin–platinum(II)
complexes and evaluated their in vitro anti-proliferative activity using a
colonic carcinoma cell line (Caco-2). They screened a number of
coumarins with an amino group at position six or seven and methyl
groups at various positions around the coumarin nucleus. These
researchers found that the most potent platinum–coumarin complex
had functional groups attached at position six. Additionally, Kostova
et al. (2001) studied the effects of coumarin complexed to zirconium.
Here again it was found that metal–coumarin complexes were more
active on their own. In 2002, Manalov et al. investigated the in vitro
cytotoxicity of a number of coumarin complexes with the late
lanthanoid transition metal, cerium, using both Burkitt lymphoma
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complexation resulted in a 40% increase in cytotoxicity, compared to the
metal-free ligand. More recently, Kostova et al. (2004) showed that
complexes of neodymium(III) and bis-coumarin ligands such as 3,3-
benzylidene-bis-(4-hydroxy-2H-1-benzopyran-2-one) and bis(4-
hydroxy-2-oxo-2H-chromen-3-yl)-pyridin-2-yl-methane could inhibit
the proliferation of a human leukemic cell line (HL-60) along with
doxycyclin-resistant variants. In addition, they showed that complexes
containing neodymium(III) could exhibit significant cytotoxic proper-
ties. Furthermore, in 2006 the same research group (Kostova et al.)
showed that zirconium(IV) complexedwith bis-coumarins could induce
a 50% inhibition of cell viability using human-derived leukemic cells and
at concentrations in the micromolar range.
Given the anti-tumour properties of metal-based coumarins and
phenanthrolines we decided to determine whether a complex (Fig. 1)
composed of each of these component parts could decrease the in
vitro proliferative activity of human cancer cell lines. Therefore, the
central objective of this study was to use a number of in vitro-based
techniques to illustrate whether this agent could selectively alter the
proliferation of cancer cells, and in doing so elucidate its molecular
mechanism of action. In addition, comparative studies were carried
out in order to highlight the potential benefits of this compound,
relative to one of the best known and most widely used metal-based
anti-cancer drugs, cisplatin.
2. Materials and methods
2.1. Test compounds and reagents
Cisplatin, 1,10-phenanthroline (phen), silver nitrate (AgNO3) and
dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich,
Ireland Ltd., and used as received. The preparation of the ligand 4-Fig. 1. Structures of (A) hncH and (B) [Ag(hnc)(phen)2 used in this study.hydroxy-3-nitro-coumarin (hncH), and the mixed-ligand silver(I)
complex, namely [Ag(hnc)(phen)2] are described in full in another
publication (Creaven et al., 2005a,b). Structure and purity were
confirmed by thin layer chromatography, infra red analysis, 1H- and
13C-NMR spectroscopy, along with elemental analysis. Based on
spectroscopic data, the structure of the silver(I) complex is believed
to be octahedral.
The chemiluminescence substrate Luminol was purchased from
Pierce Laboratories (UK), while antibodies specific to cleaved poly
(ADP-ribose)polymerase (PARP) were purchased from New England
Biolabs, and the DNA fragmentation kit was obtained from Oncogene,
UK. Jsb-1, the antibody specific for P-glycoprotein, was purchased
from Cappell, UK. All cell culture reagents and media were purchased
from Euroclone, UK, unless otherwise stated.
2.2. Model cell lines
A-498 (human kidney adenocarcinoma), HK-2 (human proximal
tubular), Chang (human hepatic), and HepG2 (human hepatocellular
carcinoma) cells were purchased from the American Type Culture
Collection, Manassas, USA. A-498, Chang, and Hep-G2 cells were
maintained in Eagle's Minimum Essential Medium (EMEM) with Earle's
Balanced Salt Solution, containing 1.5 g/L sodium bicarbonate, 2 mM L-
glutamine, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate,
100 U/ml penicillin, 100 µg/ml streptomycin and 10% (v/v) foetal bovine
serum (Sigma). HK-2 cells were maintained in Dulbecco's Modified
Eagle's Medium/Nutrient Hams F12 (50:50, v/v), supplemented with
2 mM L-glutamine, ITS (5 μg/ml bovine insulin, 5 μg/ml human
transferrin, 5 ng/ml selenium), 36 ng/ml hydrocortisone, 4 pg/ml 3,3′,5-
tri-iodo-L-thyronine, and 10 ng/ml epidermal growth factor. All cell lines
were grown at 37 °C in a humidified atmosphere with 5% CO2, and were
in the exponential phase of growth at the time of inclusion in assays.
Chinese hamster ovary cells (CHO-K1 and CHRC5) were kindly
provided by Dr. V. Ling, Ontario, Canada. CHO-K1 cells were
maintained in F-12, containing 2mM L-glutamine,100 U/ml penicillin,
100 μg/ml streptomycin and 10% (v/v) foetal bovine serum. CHRC5 cells
were maintained in EMEM, Alpha modification (without ribonucleo-
sides and deoxynucleosides), containing 2 mM L-glutamine, 100 U/ml
penicillin, 100 μg/ml streptomycin, and 10% (v/v) foetal bovine serum.
All cell lines were grown at 37 °C in a humidified atmosphere and in
the presence of 5% CO2.
2.3. Assessment of anti-proliferative activity using MTT assay
Each of the test agents, hncH and [Ag(hnc)(phen)2], phen, cisplatin,
and AgClO4 were dissolved in DMSO, diluted in culture media and
used to treat model cells over a range of drug concentrations for
periods of 4, 24, and 96 h, prior to the MTT assay. The maximum
percentage of DMSO present in any well was 0.05% (v/v). Cells were
seeded in sterile 96-well flat-bottomed plates (Sarstedt) at a density of
5×104 cells/ml and grown in 5% CO2 at 37 °C. At the end of the
required incubation period, aminiaturised viability assay using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
was carried out according to the method described by Mosmann
(1983). In metabolically active cells, MTT is reduced by the
mitochondrial enzyme succinate dehydrogenase to form insoluble
purple formazan crystals that are subsequently solubilised, and the
optical density (OD) measured spectrophotometrically. Drug-treated
cells were assayed by the addition of 20 μl of 5 mg/ml MTT in 0.1 M
phosphate buffer saline (PBS), pH 7.4. Following incubation for 4 h at
37 °C, the overlyingmediumwas aspiratedwith a syringe and 100 μl of
DMSO was added to dissolve the formazan crystals. Plates were
agitated at high speed to ensure complete dissolution of crystals and
OD was measured at 550 nm using an Anthos HT-II microtitreplate
reader. Viability was expressed as a percentage of solvent-treated
control cells. This assay had five replicates and each experiment was
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calculated and defined as the drug concentration (μM) causing a 50%
reduction in cellular viability.
2.4. Confirmation of MDR-1 phenotype
The pleotrophic drug-resistant cell line (CHRC5) has previously
been shown to over-express the MDR-1 gene product, P-glyocprotein-
170, and exhibit cross-resistance to structurally dissimilar drugs, while
P-glycoprotein-negative CHO-K1 cells fail to exhibit the MDR-1
phenotype (Hamilton et al., 1985). To confirm that these drug
phenotypes were maintained, both CHRC5 and CHO-K1 cells were
assessed for chemosensitivity by continuous exposure to a known
anti-cancer drug, vinblastin. The viability of CHRC5 and CHO-K1 cell
lines was assessed in parallel using a 96-well format with increasing
concentration of vinblastin (0–10 μM). Briefly, the cell density of both
cell lines was adjusted to 5×104 cells/ml, and 100 μl of cell suspension
was added per well to a 96-well plate (Falcon). Following overnight
incubation, a concentrated stock solution of each of the test
compounds prepared in DMSO was stored at −20 °C, thawed directly
prior to the assay, and the required dilutions were prepared by serial
dilution in complete culture medium. The maximum concentration of
DMSO present in all wells was 0.05% (v/v), a concentration which
exhibited no effect on cell morphology or growth. Viability was
determined using the MTT assay (Mosmann, 1983) as outlined in
Section 2.3. The relative degree of resistance for each cell line was
determined by comparison of the IC50 values (Carmichael et al., 1987).
2.5. DNA synthesis studies
DNA synthesis was determined using 5-bromo-2-deoxyuridine
(BrdU) colourimetric incorporation assay (Portsmann et al., 1985). A-
498 and HepG2 cells were seeded into 96-well plates and allowed to
adhere overnight. Both the ligand and the complex were added and
incubated for 96 h prior to the addition of BrdU (10 μM per well).
Plates were then incubated at 37 °C for 4 h and incorporation was
quantified by ELISA (Roche). The significance of any reduction in DNA
synthesis was determined using one-way ANOVA.
2.6. DNA binding studies
pGEM-3Z plasmid DNA was purified from Escherichia coli [strain
JM 109 as previously cultured in LB broth (Oxoid), containing 50 μg/ml
ampicillin] using a Qiagen isolation kit (Qiagen Ltd). DNA purity and
concentration was determined spectrophotometrically using A260/
A280 spectrophotometric measurements. DNA concentration was
adjusted to 1 μg/ml using 10 mM Tris–HCl, pH 7.5, containing 1 mM
EDTA. Drug binding assays were carried out using hncH and [Ag(hnc)
(phen)2], according to the method described by Lorcozio and Long
(1993). Briefly, DNA was incubated for 2 h at 37 °C, with doxorubicin
employed as a positive control. Plasmid DNA was separated on a 1%
(w/v) agarose gel in TBE (80 mM Tris–HCl, pH 8; 40 mM boric acid and
2 mM EDTA) and stained with ethidium bromide (5 μg/ml in TBE).
Bands were visualised by irradiation at 300 nm and photographed
using a Pharmaciae 3D imaging system.
2.7. Morphological analysis
Preparations of HepG2 cells were exposed to [Ag(hnc)(phen)2] for
either 4 or 24 h and stained with methylene blue and eosin (Freshney,
2000). Drug-treated cells were grown in petri dishes, washed once
with PBS, once with PBS:methanol (1:1, v/v), and then fixed in 100%
(v/v) methanol for 10 min. Following fixation, cell monolayers were
rinsed with anhydrous methanol and stained with methylene blue
and eosin for 2 min. Monolayers were then agitated for a further
2 min, destained by rinsing under a gentle stream of water and thenfinally rinsed with distilled water. Phase contrast microscopy was
carried out using a Ceti-phase contrast microscope.
Drug-treated cells were also stained using a DNA-binding agent
commonly used to stain nuclei and visualise nuclear morphology and
DNA condensation, namely 4,6-diamidino-2-phenylindole (DAPI).
Briefly, a monolayer of drug-treated cells was washed in PBS and
fixed with 4% (w/v) paraformaldehyde for 30 min at room tempera-
ture. These cells were then permeabilized with 0.2% (v/v) Triton X in
PBS and incubated with 1 μg/ml of DAPI for 30 min. Cells were again
washed three times with PBS and viewed using a fluorescent
microscope with 340/380 nm excitation filter at 250× magnification.
Apoptotic cells were confirmed by identification of intensely stained,
fragmented nuclei and condensed chromatin.
2.8. DNA fragmentation
Chromosomal DNA from drug-treated cells was extracted using the
Suicide-track™DNA ladder isolation kit (Oncogene). Briefly, cells were
cultured in 150 mm petri dishes and treated with [Ag(hnc)(phen)2] at
concentrations of 0, 20, 40 and 80 μM for 24 h. Floating cells were
collected by centrifuging, while adherent cells were harvested by
scraping and then combined with floating cells. All cells were
centrifuged and the resulting pellet consisting of approximately
5×106 cells was resuspended in 55 μl of lysis solution, followed by
the addition of 20 μl of RNase A solution and incubated at 37 °C in a
water bath for 1 h. 25 μl of DNA isolation solutionwas added and tubes
were incubated overnight at 50 °C. 500 μl of re-suspension buffer
(10 mM Tris–HCl, pH 7.5, containing 1 mM EDTA) was then added to
each sample. Intact and fragmented DNA were precipitated by the
addition of 2 μl of Pellet-paint™ co-precipitant followed by 60 μl of
3 M sodium acetate, pH 5.2 and 660 μl of 2-propanol. Samples were
mixed by inversion and then washed once in 70% (v/v) ethanol and
once in 100% (v/v) ethanol. Finally, DNA samples were air-dried and
resuspended in 50 μl of resuspension buffer (10 mM Tris–HCl, pH 6.8)
before analysis on 1.8% agarose gels. Positive controls consisted of
1×106 HL-60 cells (Human leukaemia cells) treated with 0.5 μg/ml
Actinomycin D for 24 h, as supplied by Oncogene.
2.9. Caspase activity assay
Activation of ICE-family proteases/caspases initiates apoptosis in
mammalian cells (Compton, 1992). HepG2 cells were incubated with
[Ag(hnc)(phen)2] at concentrations of 0, 20, 40 and 80 μM for 24 h.
Both floating and attached cells were collected by centrifugation and
analysed as outlined in Section 2.8. Cells, at a density of 1.5×106 cells/
ml, were counted, washed with PBS and then re-suspended in chilled
cell lysis buffer (supplied in the Caspase-3 colourimetric assay kit,
Biovision, UK). Cells were incubated on ice for 10 min and then
centrifuged for 1min at 10,000 ×g. The cytosolic fraction (supernatant)
was collected into a fresh tube and 50 µl (2 mg/ml) of each protein
samplewas transferred to a 96-well plate and diluted with lysis buffer.
A 50 µl aliquot of ×2 reaction buffer, containing 10mMDTTwas added,
followed by 5 µl of 4 mM DEVD-pNA substrate to give a final con-
centration of 200 µM. The plate was then incubated at 37 °C for 1–2 h.
OD was determined at 400 nm using an Anthos HT-II microtitreplate
reader. The fold increase in caspase-3 and -9 activities was determined
by comparing results to that obtained with un-induced control.
2.10. Immunoblot analysis for PARP cleavage
Test agent was dissolved in DMSO, diluted in culture media and
used to treat model cells growing in 100 mm petri dishes. Cells were
exposed to [Ag(hnc)(phen)2] at concentrations of 0, 20, 40 or 80 μM for
24 h. Both floating and detached cells were collected, as outlined in
Section 2.8, and washed twice with ice-cold 0.1 M PBS, pH 7.4,
harvested by scraping, then centrifuged at 8000 ×g for 5 min. Whole
Fig. 2. Dose response curve for hnc, [Ag(hnc)(phen)2 and phen using (A) Hep-G2and
(B) A-498 cells, following 96 h incubation, as assessed by MTT assay. In both cell lines,
the complex and 1,10-phenanthroline produced the greatest concentration-dependent
decrease in cellular proliferation. Results are expressed as percentage viability of
solvent-treated control cells. Bars indicate±S.E.M., n=3.
Fig. 3. Dose response curve for [Ag(hnc)(phen)2] using HepG2, Chang, A-498 and HK-2
cells following 96 h incubation, as assessed by MTT assay. The complex was produced
the greatest concentration-dependent decrease in cellular proliferation in both
neoplastic-derived cancer cells lines (HepG2 and A-498). Results are expressed as
percentage viability of solvent-treated control cells. Bars indicate±S.E.M., n=3.
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lysing solution (Pierce, UK)], supplemented to contain 1 mM EDTA,
1 mM EGTA, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl
fluoride (PMSF), 2 μg/ml leupeptin and 2 μg/ml aprotinin. After 15 min
on ice, the mixture was clarified by centrifugation for 5 min at
10,000 ×g and the resultant supernatant collected. 40 μg of total
protein lysates were resolved using electrophoresis on a 12%
polyacrylamide gel (PAGE) and transferred to nitrocellulose mem-
branes. The level of protein expression was determined using specific
primary antibodies, followed by peroxidase-conjugated secondary
antibodies and visualisation by a chemiluminescent substrate (Lumi-
nol) and exposure to X-ray film.
2.11. Cell cycle analysis
HepG2 cells were grown in 100 mm Petri dishes and exposed to
either solvent or [Ag(hnc)(phen)2] at concentrations of 0, 20, 40 and
80 μM for 24 h. Both floating and attached cells were collected by
centrifugation (Section 2.8), washed twice in ice-cold PBS, pH 7.4,
harvested by trypsinisation, and then collected by centrifugation. The
effect of drug treatment on cell cycle progression was determined
using flow cytometric analysis according to the method of Nunez
(2001). Briefly, cell suspensions were fixed and permeabilised by
vigorous addition of nine volumes of ice-cold 70% (v/v) ethanol andstored at −20 °C for a minimum of 24 h, prior to analysis. Cells at a
density of approximately 1×106 were re-suspended in 800 μl of
propidium iodide staining solution (20 μg/ml propidium iodide and
200 μg/ml RNase A in PBS, pH 7.4) and incubated in the dark at room
temperature for 30 min. The percentage of cells in the sub-G1, G0/G1, S
and G2/M phases of the cell cycle was determined over a range of
concentrations and time points, and analysed from at least three
independent experiments using Cell Quest™ software (Becton
Dickinson).
2.12. Statistical analysis
Statistical analyses were performed using the statistical software
package Mini-tab®. Statistical evaluation of the untreated control cells
along with drug- and solvent-treated cells was calculated using one-
way ANOVA (analysis of variance). A probability of 0.05 or less was
deemed statistically significant. The following notation was used
throughout; ⁎Pb0.05, ⁎⁎Pb0.01 and ⁎⁎⁎Pb0.001, relative to control.
3. Results
3.1. Anti-proliferative and cyto-selective properties
hncH and [Ag(hnc)(phen)2], shown in Fig. 1, along with 1,10-
phenanthroline (phen), cisplatin and AgClO4 were initially incubated
with four human-derived cell lines, two carcinoma (A-498 and
HepG2) and two non-carcinoma (Chang and HK-2) and the anti-
proliferative effect determined usingMTT. Data obtained for hncH, [Ag
(hnc)(phen)2] and phen following 4 and 24, along with 96 h
continuous incubation was used to calculate IC50 values and shown
in Figs. 2 and 3, along with Table 1. All compounds displayed a
concentration- and time-dependent anti-proliferative profile across
all four cell lines, with HepG2 cells being the most sensitive. Also,
based on both the dose–response curves (Figs. 2 and 3) and the IC50
value calculated, it would appear that [Ag(hnc)(phen)2] was statisti-
cally more active than the parent ligand. In order to prove that the
cytotoxicity observed was due to the complex rather than the simple
silver salt, it was decided to include AgClO4 in the test protocol. The
data presented in Table 1 suggests that although the ligand is not as
cytotoxic as the metal complex, the other component part of the
ligand, namely phen, is equally cytotoxic. In addition, we investigated
the possibility that the complex could act as potent anti-proliferative
agents in neoplastic-derived (HepG2 and A-498), rather than non-
neoplastic-derived (Chang and HK-2) cell lines. The results presented
in Table 1 would suggest that HepG2 cells were significantly more
Table 2
Anti-proliferative activity and resistance factor used to confirm multi-drug resistance
phenotype and to demonstrate whether [Ag(hnc)(phen)2] was a substrate for P-gp
Test agent CHO-K1 CHRC5 Resistance factor
IC50 (μM)±S.E.M. IC50 (μM)±S.E.M.
[Ag(hnc)(phen)2] 31±1.6 19±2.2 0.6
Vinblastine 0.013±0.005 0.48±0.04 37
The resistance factor was calculated by division of the IC50 for the CHRC5 cell line by the
IC50 for the CHO-K1 cell line. Results presented are representative of three independent
experiments.
Table 1
Anti-proliferative activity of test agents was determined using HepG2, Chang, A-498,
and HK-2 cells, following 96 h continuous incubation and MTT assay
Compound Hep-G2 Chang A-498 HK-2
IC50
(µM)±
S.E.M.
IC50
(µM)±
S.E.M.
IC50
(µM)±
S.E.M.
IC50
(µM)±
S.E.M.
hncH 220±2.8 N250 198±2.6 N250
[Ag(hnc)(phen)2] 3.8±1.4a 18±2.6a 15±0.9a 3±0.7a
AgClO4 7.0±0.7 19.0±1.8 44.0±2.3 63.0±2.4
Phen 4.5±0.9 7±1.2 5.5±1.2 9±1.5
Cisplatin 15.0±2.65 45±2.9 14.0±2.3 18±2.7
A graph of viability versus drug concentrationwas used to calculate all IC50 values (μM),
n=5.
a Indicates value is statistically distinct from that of the parent ligand at Pb0.05.
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reflected in the non-neoplastic renal HK-2 cells. Thus, there is
insufficient evidence to conclude that the complex can act in a cyto-
selective manner i.e. capable of sparing non-neoplastic cells. Further-
more, the IC50 values obtained for cisplatin were shown to be either
similar to or over three times greater when using the A-498 and
HepG2 cells, respectively. Taken together, the data presented would
suggest that the complex was capable of exhibiting a similar or greater
in vitro anti-proliferative profile to that seen with cisplatin.
In order to provide information on the anti-proliferative effect of
this complex following relatively short exposure times, MTT-based
viability assays were conducted at both 4 and 24 h and the IC50 was
calculated to be 80 and 40 μM, respectively, for the most sensitive cell
line, HepG2 (Fig. 4). Consequently, these concentrations and time-
pointswere selected for inclusion in all assays unless otherwise stated,
and used to probe the molecular mechanism of action of the complex.
It has been established that over-expression of P-glycoprotein-170
is responsible for the “classical” type of multi-drug resistance. This has
been defined as the simultaneous resistance of a cell against a variety
of structurally dissimilar cytotoxic drugs (Gottesmann et al., 1996;
Tellingen, 2001). Using a cellular model of MDR-1, we confirmed the
multi-drug resistant phenotype by immunological detection of P-
glycoprotein-170 along with chemosensitivity testing using vinblas-
tine. This method allows the multi-drug resistant phenotype to be
assessed by detection of the protein effector molecule and by
comparison of the relative toxicities (IC50) in the multi-drug resistant
positive and negative cell lines. Consequently, drugs that display lesser
or equal effects in the multi-drug resistant positive cell line could beFig. 4. Dose response curves for [Ag(hnc)(phen)2] using HepG2 cells following 4 and
24 h incubation, as assessed byMTTassay. This complex produced both a concentration-
and time dependent decrease in cellular proliferation. Results are expressed as
percentage viability of solvent-treated control cells. Bars indicate±S.E.M., n=3.described as substrates for P-glycoprotein-170, thus providing a
mechanism by which they can be removed from the cell, thus
preventing cell death. Furthermore, comparison of the relative
experimental toxicities allows calculation of a resistance factor. This
factor was calculated by dividing the drug toxicity (IC50 value)
observed in the multi-drug resistant positive cells by the drug toxicity
in the multi-drug resistant negative cells. In addition, the integrity of
the two model cells lines was confirmed by Western blot analysis. P-
glycoprotein-170 was not detected in the multi-drug resistant
negative cells (CHOK1), while there was considerable P-glycopro-
tein-170 expression in multi-drug resistant positive cells (CHRC5)
(data not shown). The results presented in Table 2 show the data
obtained for vinblastine and the test complex. These results indicate
that the multi-drug resistant phenotype of CHRC5 cells was retained,
and that vinblastine demonstrated a resistance factor of 37. This value
is consistent with a previously published value of 40 (Finn et al.,
2004b; Thati et al., 2007a,b). In contrast, data obtained for theFig. 5. The effects of hnc and [Ag(hnc)(phen)2] on DNA synthesis in both (A) HepG2 and
(B) on A-498 cells was determined using BrdU assays, following 96 h incubation. The
complex produced the greatest concentration-dependent decrease in DNA synthesis
and in both cell lines. Results are expressed as percentage viability of solvent-treated
control cells. Bars indicate±S.E.M., n=3.
Fig. 6. Electrophoretic mobility shift assays were used to determine the effects of [Ag
(hnc)(phen)2] on the migration of pGEM-3Z supercoiled plasmid DNA for 2 h at 37 °C.
Agarose gels were stained with ethidium bromide. Results indicate that the complex did
not inhibit the migration of super-coiled (SC), linear (L) or open circular (OC) forms of
plasmid DNA, suggesting that it did not intercalate DNA. Lane 1 pGEM-3Z DNA (negative
control); lane 2 positive control (pGEM-3Z DNA and doxorubicin, 10 μM); lanes 3–5
pGEM- 3Z DNA and complex (1, 10, and 200 μM). Results presented are representative of
three independent experiments.
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suggesting that the complex is not a potential MDR-1 substrate, and so
would not be removed from the cell by this mechanism. In addition,
greater cytotoxicity was observed in the multi-drug resistant positive
cell line, rather than the multi-drug resistant negative cell line,
suggesting it is effective in killing cells expressing high levels of P-
glycoprotein-170 (Table 2).
3.2. Inhibition of DNA synthesis and intercalation
In an attempt to elucidate the events responsible for the observed
reduction in cellular proliferation, the effect of [Ag(hnc)(phen)2] on
DNA synthesis was determined using BrdU incorporation assays.
Results obtained suggest that [Ag(hnc)(phen)2] caused a dose-
dependent decrease in DNA synthesis, across the two model
neoplastic cell lines, HepG2 and A-498 (Fig. 5).
The relationship between the observed cytotoxic response and the
possibility that DNA was a molecular target was determined by
carrying out intercalation studies, using electrophoretic mobility shift
assays. Treatment of pGEM-3Z plasmid DNA with the complex atFig. 7. Effect of [Ag(hnc)(phen)2] on HepG2 cellular morphology following exposure for 4 a
morphology was assessed usingmethylene blue and eosin alongwith phase contrastmicrosc
4 h, resulted in a visible thinning of the monolayer, with cells appearing vacuolated (arrow
nuclear shrinkage and disintegration (arrows). Control cells treated with vehicle alone retain
are representative of three independent experiments.concentrations of 1,10 and 200 µMdid not alter themigration of any of
the three forms of DNA (super-coiled, linear, or open-circular), unlike
the positive control doxorubicin (Fig. 6). This indicates that the
complex does not function through DNA intercalation.
3.3. Morphological analysis and induction of cleaved PARP
The cytological effects of treatment with the complex at concen-
trations of 0, 20, 40 and 80 µM for either 4 or 24 h were determined
using methylene blue and eosin (Fig. 7), along with DAPI staining
(Fig. 8) and standard light microscopy. The results presented in Fig. 7
clearly suggest that [Ag(hnc)(phen)2] at a concentration of 20 μM
(panel D) and as early as 4 h resulted in visible thinning of the
monolayer, with nuclear disintegration and vacuolation of the
cytoplasm. These changes are generally considered to be characteristic
of the induction of both apoptotic and necrotic cell death. In contrast,
treatment of cells with vehicle alone (Fig. 7A) appeared to have no
visible effect, as cells retained the typical epithelial morphology
associated with Hep-G2 cells.
The effect of the complex on the integrity of DNA isolated from
treated cells was determined using DAPI staining. This stain is
commonly used to visualise nuclear morphology and detect the
presence of DNA condensation. Results presented in Fig. 8 showed that
following 24 h, cells exposed to the complex at a concentration of 20,
and particularly 40 and 80 µM, caused nuclear shrinkage (panels B, C,
and D, respectively). Furthermore, concentrations of 40 and 80 µM
caused nuclei to become enlarged, intensively stained, and nuclear
material appeared fragmented (panels B to D). Taken together, these
results suggest the presence of both apoptotic and necrotic cell death.
Analysis of DNA from apoptotic cells by agarose electrophoresis is
known to produce a characteristic DNA ladder that is widely regarded
as a biochemical hallmark of apoptosis. Therefore, in order to further
clarify the results observed in both Figs. 7 and 8, genomic DNA was
extracted from drug-treated cells. Both floating and attached cells
were collected for electrophoresis. Results presented in Fig. 9 illustrate
that the complex was capable of inducing a dose-dependant increase
in 180 base-pair multimeric bands, particularly at a concentration of
80 μM. Finally, it is worth noting that no DNA fragmentation was
observed following 4 h incubation (data not shown), suggesting that and 24 h to concentrations of 0, 20, 40 and 80 μM (Panels A–D, respectively). Cellular
opy (60×magnification). Treatment at concentrations of 20, 40 and 80 μM, and as early as
). Furthermore, by 24 h and at concentrations of 40 and 80 μM, there was progressive
ed the typical epithelial morphology associated with HepG2 cells. The results presented
Fig. 8. Effect of [Ag(hnc)(phen)2] on HepG2 cellular morphology was determined following treatment at concentrations of 0, 20, 40 and 80 μM (Panels A–D, respectively) for 4 h and
24 h using DAPI staining and fluorescence microscopy (340/380 nm excitation, 60× magnification). Apoptotic nuclei appeared intensively stained, nuclei were fragmented and
chromatin condensed (arrows). These changes appeared following 24 h treatment and at concentrations of 20, 40 and 80 μM. In contrast, control cells (Panel A) produced no visible
effect on the epithelial morphology. Results presented are representative of three independent experiments.
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produce the observed effects.
3.4. Biochemical assays to detect cell death
Caspase-3 is known to be one of the main executioner/effector
caspases which is activated by caspase-9 (Compton, 1992; Los et al.,
2003; Oliver and Vallette, 2005; Kuribayashi et al., 2006). The results
presented in Fig. 10 show the fold increase in both caspase-3 and -9Fig. 9. Internucleosomal DNA cleavage in Hep-G2 cells treated with [Ag(hnc) (phen)2] as
a marker of apoptosis. Hep-G2 cells were grown in medium and in 150 mm petri dishes
and treated with either solvent vehicle or [Ag(hnc) (phen)2] (Lanes 4–6, 20, 40 and
80 μM, respectively) for 24 h. Both floating and attached cells were collected by
centrifugation and fragmented and intact genomic DNA was extracted using the
Suicide-track™ DNA ladder isolation kit. DNA samples were separated using agarose
electrophoresis and stained using ethidium bromide. Drug treatment resulted in the
presence of 180 bp multimer bands, considered to be indicative of apoptotic cell death.
Lane 1: molecular weight markers, Lane 2: positive control provided in the kit which
consisted of 1×106 HL-60 cells (Human leukaemia cells) treated with 0.5 μg/ml
Actinomycin D for 24 h, and Lane 3 consisted of a negative control where Hep-G2 cells
were treated with medium alone. Results presented are representative of three
independent experiments.activities following 24 h incubation. The activity of caspase-3 was
significantly increased as a result of exposure to the complex at
concentrations of 20, 40, and 80 μM. However, caspase-9 activity only
changed following exposure to the highest concentration studied.
The results presented in Fig.10 suggests that if apoptosiswere to be
caspase-dependant there would be a corresponding increase in
cleavage of poly(ADP-ribose)-polymerase protein (PARP), a known
consequence of caspase-3 activation. This theory was subsequently
confirmed using Western Blot Analysis (Fig. 11), where [Ag(hnc)
(phen)2] at concentrations of 40 and 80 µM was seen to increase the
expression of cleaved PARP. However, this increase was not seen at the
lower concentration of 20 μM (data not shown). Taken together with
the results obtained from the caspase assays, it would indicate that aFig. 10. Effects of [Ag(hnc)(phen)2] on caspase-3 and -9 activity, using colorimetric
protease assay. HepG2 cells were treated with drug concentrations at concentrations of
20, 40 and 80 μM for 24 h. Following drug-treatment, cells were lysed, protein con-
centration was assayed, and diluted to 1 mg/ml. The fold-increase in caspase-3 and -9
was determined by comparisonwith that of the solvent vehicle control. Drug treatment
with all test concentrations resulted in a statistically significant dose-dependent
increase in both caspase-3 activity. Results are representative of three independent
experiments. Bars indicate±S.E.M. The asterisks indicate statistically significant
difference to control: ⁎Pb0.05, ⁎⁎Pb0.01 and ⁎⁎⁎Pb0.001.
Fig. 11. Effect of [Ag(hnc)(phen)2] on the proteolytic cleavage of poly(ADP-ribose)
polymerase (PARP) in HepG2 cells, following 24 h incubation with drug concentrations
of 40 and 80 μM (lanes 1 and 2, respectively). Both floating and attached cells were
collected and analysed. A band corresponding to cleave PARP (85 kDa) was detected
following drug-treatment at concentrations of 40 and 80 μM (Panel A, lanes 1 and 2,
respectively). The same lysates were probed for the presence of β-actin at (42 kDa) as a
normalisation control (panel B).
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dependent apoptotic cell death through activation of both caspases-3
and -9, with subsequent cleavage of PARP.
3.5. Inhibition of cell cycle progression
The effect of the complex on cell cycle events was examined and
the resultant histograms were also studied for evidence of apoptotic
cell death. HepG2 cells were exposed to test agent (20, 40, and 80 μM)
for 24 h and the percentage of cells entering each phase of the cell
cycle was determined. Examination of the histograms (Fig. 12A)
indicated the presence of a sub-G1 peak which increased with
increasing drug concentrations (40 and 80 μM), particularly at theFig. 12. Effects of [Ag(hnc)(phen)2] at concentrations of 0, 20, 40 and 80 μM on cell cycle pr
harvested, alcohol fixed and stained with propidium iodide. Cell cycle distribution was dete
cytometric analysis. Sub-G1 peaks indicate cell death by apoptosis, as indicated by arrows (highest concentration studied. It should be noted that this highest
concentration produced a statistically significant increase in the
activity of both caspase-3 and -9 (Fig. 10). Furthermore, the results
presented in Fig. 12B show a concentration-dependent decrease in the
% of cells entering G0/G1 and G2/M. In addition, the % in S phase
increased at the lower drug concentration (20 and 40 μM) and
subsequently decreased at the highest concentration studied (80 μM).
Finally, the histograms presented in Fig. 12A would indicate that
HepG2 cells may be polyploid. We suggest that this is likely to be due
to cell clustering resulting from a difficulty in the preparation of a
single cell suspension, rather than any effect of the complex, as this
effect was also present in solvent-treated control cells.
4. Discussion
The primary objective of this study was to determine the anti-
proliferative properties of 4-hydroxy-3-nitro-coumarin-bis(phenan-
throline) (hncH) and its silver(I) complex, 4-oxy-3-nitro-coumarin-bis
(phenanthroline), ([Ag(hnc)(phen)2]). We also attempted to deter-
mine whether this complex could selectively kill human cancer cells,
leaving non-neoplastic cells viable. In addition, we sought to elucidate
the cellular targets which were central to understanding the
molecular mechanism of this compound. In order to highlight the
potential advantage of this compound, comparative studies were
carried out using one of the best known and most widely used metal-
based anti-cancer drugs, cisplatin. Furthermore, this is the first study
of its kind to determine the potential application of this complex as a
novel anti-proliferative agent.
Initial cytotoxicity studies were carried out to determine the IC50
value for both the ligand and the metal complex, along with the simple
metal salt Ag(ClO4), phen, and cisplatin, using all four human-derived
model cell lines. It was intended that this approach would allow us to
determine if the observed anti-proliferative effect was seen with the
entire silver–coumarin-phen complexonly or fromeither themetal-free
ligand, phen, or the simple aquated silver metal ion. Additionally,ogression in HepG2 cells following 24 h incubation. Cells were grown in 6 well plates,
rmined by calculating the percentage of cells in each phase of the cell cycle, using flow
panel A). Histograms presented are representative of three independent experiments.
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from neoplastic origin and the other from non-neoplastic, it was hoped
that this might provide a means by which the potential selective nature
of the complex could be identified. The results obtained from the initial
viability studies (Figs. 2–4, along with Table 1) showed that following 4,
24 and 96 h exposures showed that the complex displayed both a
concentration- and time-dependantanti-proliferative effect. In addition,
based on IC50 values presented in Table 1 alone, it appeared that the
complex was more active than the metal-free ligand, phen, the metal
salt or cisplatin. Furthermore, Hep-G2 cells were shown to be most
sensitive, with the complex being four times more active than cisplatin.
The results obtained also suggest that HepG2 cells were significantly
more sensitive than Chang, but this effect was not seen with the non-
neoplastic renal (HK-2) cells. The concentration chosen for subsequent
assayswere selected on the basis that they represented the IC50, half the
IC50, and finally double the IC50 and at 24 h incubation. In this way, the
relatively short-term effects of the complex on key cellular targets could
be determined. This approached is underpinned by the findings of Kim
et al. (2005) who suggested that relatively short incubation times are
appropriate when studying apoptotic cell death.
Consequently, it would appear that like cisplatin, the complex was
capable of reducing the proliferative capacity of cells, but not always in
a cyto-selective manner. Furthermore, the structure of the metal-
complex is such that it possesses two phens. However, when this is
considered and the results for phen are compared with that of the
complex, it would appear that what sets the complex apart is not
simply the recorded IC50 values but also the apparent cyto-selectivity,
particularly when comparing the results obtained using HepG2 and
Chang cells. It was this combination of properties which encouraged
us to probe the mechanism of action of the complex, and especially in
the Hep-G2 model cell line.
Having observed the cytotoxic effect of the complex, we next
sought to determine the morphology effects of drug treatment.
Consequently, two different staining techniques were employed.
Methylene blue and eosin was used to determine whether gross
morphological changes could be observed. The second used was DAPI
which visualised nuclear morphology and detection of DNA con-
densation. Results presented in Figs. 7 and 8 clearly show that the
complex could induce changes which were consistent with the
induction of cell death by both apoptosis and necrosis. Based on the
data presented, we suggest that the mode of cell death may be
dependent on both drug concentration and incubation time. Conse-
quently, we postulated that the mode of cell death may be apoptosis
with secondary necrosis.
In an attempt to provide evidence for the involvement of many of
the biochemical processes which are central to controlling the under-
lying mechanisms, it was decided to study of number of key features of
cell death. Therefore, additional studies were carried out using genomic
DNA isolated from drug-treated cells. Cleavage of genomic DNA by
endogenous endonucleases during apoptosis is an irreversible event
that commits the cell to die (Blatt and Click, 2001). The results
presented in Fig. 8 show that by 24 h drug-treated cells had activated
the necessary endonucleases, such that endonucleolytic cleavage of
DNA at internucleosomal linker sites had occurred, leading to the
production of 180–200 bp mono- and oligo-nucleosomal fragments. In
addition, increasing drug concentration caused band smearing, sug-
gesting the possible induction of necrotic cell death. This finding served
to underpin the morphological results obtained by DAPI staining (Fig.
8). Our research group have recently studied the in vitro effect of two
silver-based-derivatives of coumarin using cancer cell lines (Thati et al.,
2007a,b). In both cases, apoptosis and necrosis was observed using both
cytology and DNA analysis. However, as in the current study, it proved
very difficult to discriminate fully between the two forms of cell death.
Consequently, here we suggest that the complex may cause apoptotic
cell death, and in the absence of phagocytotic cells, the apoptotic bodies
lyse, leading to signs of secondary necrosis.It is now widely accepted that activation of the caspase cascade
occurs upstream of DNA fragmentation (Compton, 1992; Kuribayashi
et al., 2006). This activation serves to induce the proteolytic cleavage
of a wide range of substrates. Caspase-3 is known to cleave and
inactivate the inhibitor of caspase-activated DNAase, which in turn
causes the release of active endonucleases which translocate into the
nucleus in order to activate internucleosomal DNA fragmentation,
ultimately serving as a trigger for phagocytosis (Compton, 1992;
Nagata, 2000). In addition, caspase-3 activation leads to increased
cleavage of PARP, a known substrate for caspase-3 (Nagata, 2000).
Proteolytic cleavage of native PARP (116 kDa) results in separation of
the N-terminal binding domain (24 kDa) from its C-terminal catalytic
domain (89 kDa), (Kartner et al., 1993; Yang et al., 2006). This cleavage
is known to be an early critical event required for tumour cells that
have been exposed to DNA-damaging agents and have committed to
die by apoptosis. Therefore, we decided to investigate the involvement
of caspase-3 and -9 in the action of the complex (Fig. 10). Data
obtained demonstrate that the complex could mediate the activity of
both caspase-3 and -9 leading to PARP cleavage. Taken together, the
results presented indicate that exposure to the complex caused cell
death which was both caspase and PARP-dependent.
In 2007, our research group studied the potential in vitro anti-
proliferative effect of threemetal complexes of phen including copper,
silver, and manganese, using human-derived cancer cell lines (Deegan
et al., 2007). Results from limited mechanistic studies on these
complexes have shown that like the complex studied here, all of these
agents, and at similar concentrations, could decrease cell proliferation
and were more active that cisplatin. Furthermore, these complexes
appeared to function in a manner very similar to that described here.
Taken together, these results presented here suggest that the metal
and phen components may be central to augmenting the anti-
proliferative activity.
Recently, Heffeter et al. (2006) showed that a lanthanium complex
of phen, namely [tris(1,10-phenanthroline)lanthanium(III)trithiocya-
nate], could induce apoptosis in human-derived cell lines. They
showed that by 24 h, the complex (5 μM) caused condensation of
chromatin, along with nuclear fragmentation. In addition, they
showed that this effect was mediated through activation of caspase-
3 and -7, leading to cleavage of poly(ADP-ribose)polymerase (PARP).
Based on these findings, the authors suggested that mitochondria
were central in controlling this effect.
The ability of the complex to either intercalate with DNA or inhibit
its synthesis was examined. The results presented in Fig. 6 clearly
demonstrate that the complex was incapable of intercalating DNA, but
it caused a concentration-dependant decrease in its synthesis (Fig. 5).
Therefore, based on these finding, wewere confident that the effect on
DNA synthesis was linked, not just to an anti-proliferative effect, but
also to the machinery associated with cell division, and ultimately an
ability to induce cell death.
In order to explore this hypothesis further, we decided to use flow
cytometric analysis to determine if the complex could disturb cell
division. In addition, the resultant histograms were examined for
evidence of apoptotic and/or necrotic cell death. Consequently, Hep-
G2 cells were exposed to test agent (20, 40, and 80 μM) for 24 h and
the percentage of cells entering each phase of the cell cycle was
determined. The results obtained suggested that the complex was
capable of preventing cell cycle progression since the % of cells
entering G0/G1 and G2/M was decreased in a concentration-
dependant manner. Furthermore, the % of cells in S phase increased
at the lower concentrations and subsequently decreased at the higher
concentrations. It is well established that cell cycle progression is a
tightly ordered and regulated process involving multiple checkpoints.
These checkpoints respond to a variety of growth signals, alterations
in cell size, and DNA integrity (Garrett et al., 2001; Giacinti and
Gioradano, 2006; Tao and Lin, 2006). We postulate that the complex
may act on these checkpoints, preventing further cell division and
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this theory has not yet been proven experimentally. Furthermore, we
suggest that when cells were exposed to the higher drug concentra-
tions (40 and 80 μM), it may have caused them to undergo necrotic cell
death, and by a mechanismwhich is caspase-dependent (Fig. 10). This
theory may help explain the findings presented in Fig. 8, using DAPI
staining, where cells display characteristics consistent with necrotic
cell death. Examination of the flow cytometric histograms (Fig. 12A)
indicated the presence of a sub-G1 peak which increased with
increasing drug concentration (40 and 80 μM). Taken together, these
data suggest that cell death may occur via a caspase-independent
mechanism with a concurrent blockage in cell cycle events. However,
there remains the possibility that this can switch to a caspase-
dependent mechanism, in response to drug concentration.
Previously, Zhou et al. (2002) reported that a Cu(II)phen complex
could induce apoptotic cell death in a liver carcinomacell line (Bel-7402)
using Hoechst 33258 staining. Furthermore, they used flow cytometric
analysis and electrophoresis to show the presence of a concentration-
dependent sub-G1 peak and DNA laddering, respectively. Furthermore,
these researchers used concentrations of 30, 60, or 180 μM and an
incubation time of 3 h, which are similar to the conditions used in the
current study. Consequently, the results presented here are broadly
similar to literature values, albeit for a metal–phen complex.
Recently, our research group has studied the in vitro anti-
proliferative activity of a silver–coumarin derivative, namely 6-
hydroxycoumarin-3-carboxylatosilver, using human cancer cells.
Results from these studies showed that this compound was capable
of inducing apoptotic cell death through activation of caspases-3 and
-9, leading to cleavage of PARP. In addition, it was seen to function
through an alteration in cell cycle progression, with a decrease in the
percentage of cells entering G0/G1. Furthermore, all of these pro-
apoptotic events were seen to occur as early as 24 h post drug-
treatment (Thati et al., 2007b). Taken together, the results obtained
with the silver–coumarin derivative are very similar to those
obtained here, suggesting that both compounds may function by
targeting common cellular targets, and may represent a family of
metal–coumarin–phen complexes which are worthy of further
investigation.
In conclusion, results from this study clearly indicate that [Ag(hnc)
(phen)2] functions as a potent anti-proliferative agent in vitro. In
addition, its in vitro activity was shown to be in the micromolar range,
which is similar to activities obtained with phen-based compounds
complexed with ruthenium, chromium, and lanthanum complexes, as
described above. In addition, all of these agents were shown to induce
apoptotic cell death, but DNA intercalation did not appear to be
essential for mediating its activity. This suggests that all of these
compounds function on broadly similar cellular targets.
Additional studies are currently underway in order to determine
whether [Ag(hnc)(phen)2] retains its activity in a cisplatin-resistant
cell line. Furthermore, the inclusion of parent ligand, phen, and the
simple salt in detailed mechanistic studies would allow us to
understand the role that each of the component parts plays in
mediating the observed response. Thus, these experiments will form a
significant portion of the intended future studies, along with
elucidation of the inter-relationship between these regulatory
proteins and those associated with signalling proteins, such as the
mitogen-activated protein kinases which are known to control cellular
proliferation, death, and differentiation (Hoshino et al., 2001).
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